LOGIN OR REGISTER
Course Library

Raising the Bar for Patient Outcomes With Immunotherapy in Early-Stage Resectable NSCLC

Oncology
Curriculum:
Raising the Bar for Patient Outcomes With Immunotherapy in Early-Stage Resectable NSCLC
Credits:
0.5 AMA PRA Category 1 Credit(s) ™
Launch Date:
November 17, 2022
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Oncologists, oncology NPs, oncology PAs, oncology nurses, pulmonologists, pulmonology NPs, pulmonology PAs, pathologists, and pharmacists

Relevant Terms:

Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Immunotherapy

Heather Wakelee, MD, FASCO

Professor of Medicine 
Chief, Division of Oncology
Stanford University School of Medicine
Interim Medical Director, Stanford Cancer Center
Deputy Director, Stanford Cancer Institute
President, International Association for the Study of Lung Cancer (IASLC)
Stanford, CA 

Heather Wakelee, MD, FASCO, is a Professor of Medicine and Chief of the Division of Oncology at Stanford University, Deputy Director of the Stanford Cancer Institute, and Interim Medical Director of the Stanford Cancer Center. Dr Wakelee serves as the President of the International Association for the Study of Lung Cancer (IASLC). She is a Fellow of the American Society of Clinical Oncology (FASCO). Dr Wakelee is a graduate of Princeton University and Johns Hopkins University School of Medicine. She completed her postgraduate training at Stanford University.

As an experienced lung cancer investigator, Dr Wakelee has authored or co-authored over 200 medical articles on lung cancer and thymic malignancies. She is involved in dozens of clinical trials involving adjuvant therapy, immunotherapy, and anti-angiogenesis agents. Her research focuses on many specific lung cancer subtypes defined by specific mutations in EGFR, ALK, ROS1, RET, BRAF, and others. Her translational efforts have involved collaborations with colleagues in medical oncology, thoracic radiation oncology, thoracic surgery, radiology, pulmonary medicine, and population sciences.

Meghan Ramsey, MD

Clinical Associate Professor
Division of Pulmonary, Allergy, and Critical Care Medicine
Critical Care Medicine Fellowship Program Director
Stanford University School of Medicine
Interim ICU Medical Director
Stanford Health Care ValleyCare 
Stanford, CA

Meghan Ramsey, MD, is a Clinical Associate Professor in the Division of Pulmonary, Allergy, and Critical Care Medicine at Stanford University. She received her undergraduate degree from Lafayette College in Easton, Pennsylvania, with a major in Neuroscience. Dr Ramsey received her medical degree from Stanford University, where she stayed to complete her internal medicine residency and pulmonary/critical care fellowship. 

Dr Ramsey’s clinical time is split between the inpatient setting in the medical ICU and the ambulatory setting in Interventional Pulmonology with a focus on thoracic malignancies. Outside of her clinical time she has a dedicated commitment to teaching, serving as a mentor for residents and fellows, as well as leading as a co-director the pulmonary physiology course for medical students.

1. SELECT patients with early-stage resectable NSCLC who may derive benefit from immunotherapy
2. RECOMMEND immunotherapy as a component of multimodal therapy in early-stage resectable NSCLC according to recent clinical trial data and patient preferences

SPONSORSHIP & SUPPORT

This educational activity is jointly provided by the Postgraduate Institute for Medicine and Spire Learning. 

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

PROGRAM OVERVIEW
Are you up to date on the role of immunotherapy in the setting of non-small cell lung cancer (NSCLC)? In this educational activity, experts Heather Wakelee, MD, and Meghan Ramsey, MD, explore how to select patients with early-stage resectable NSCLC who may derive benefit from immunotherapy and how to recommend immunotherapy for NSCLC according to clinical data and patient-specific factors. This immersive activity will challenge your clinical decision-making specific to NSCLC through two patient case scenarios developed to demonstrate pathways to improving patient care for patients with NSCLC. 

TARGET AUDIENCE
The target audience for this educational initiative is oncologists, oncology NPs, PAs, and nurses, pulmonologists, pulmonology NPs and PAs, pathologists, and pharmacists.

LEARNING OBJECTIVES
Upon completion of this educational activity, learners should be better able to:
  • SELECT patients with early-stage resectable NSCLC who may derive benefit from immunotherapy 
  • RECOMMEND immunotherapy as a component of multimodal therapy in early-stage resectable NSCLC according to recent clinical trial data and patient preferences

ACCREDITATION AND CREDIT DESIGNATION

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Spire Learning. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
 


Physician Continuing Medical Education 
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

HOW TO RECEIVE CREDIT
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  • Read the learning objectives, disclosure statements, and other introductory CME information
  • Complete the preassessment prior to the start of the activity
  • Participate in the online enduring activity
  • Complete the postassessment with a passing grade of 80% or higher, and evaluation at the conclusion of the activity
If you are seeking credit, you must complete the postassessment and evaluation at the conclusion of the activity. Certificates will be emailed to the participant.

For CME questions please contact: inquiries@pimed.com

CONFLICTS OF INTEREST STATEMENT
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Heather Wakelee, MD, FASCO (Chair)
Professor of Medicine 
Chief, Division of Oncology
Stanford University School of Medicine
Interim Medical Director, Stanford Cancer Center
Deputy Director, Stanford Cancer Institute
President, International Association for the Study of Lung Cancer (IASLC)
Stanford, CA 

Disclosures:
Grant/Research Support: ACEA Therapeutics; Arrys Therapeutics; AstraZeneca; Bristol-Myers Squibb Company; Clovis Oncology; Genentech, A Member of the Roche Group; Helsinn Group; Merck & Co, Inc; Novartis Pharmaceuticals Corporation; SeaGen Inc; Xcovery 
Consultant/Advisory Board: AstraZeneca; Genentech, A Member of the Roche Group; Merck & Co, Inc; Mirati Therapeutics, Inc

Meghan Ramsey, MD
Clinical Associate Professor
Division of Pulmonary, Allergy, and Critical Care Medicine
Critical Care Medicine Fellowship Program Director
Stanford University School of Medicine
Interim ICU Medical Director
Stanford Health Care ValleyCare 
Stanford, CA

Disclosures:
No relevant financial relationships with any commercial interests.


All of the relevant financial relationships listed for these individuals have been mitigated.

EDUCATIONAL PLANNING COMMITTEE
The PIM planners and managers have nothing to disclose. The Spire Learning planners and managers have nothing to disclose.

OFF-LABEL STATEMENT
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

PRIVACY POLICY:
Spire Learning Privacy Policy:
Spire Learning, LLC is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.
 
Collection and Use of Your Personal Information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected and retained, and used by Spire Learning, LLC to continuously improve the learning experience.
 
Spire Learning, LLC will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws. 

COPYRIGHT INFORMATION:
All rights reserved - Postgraduate Institute for Medicine. No part of this program may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embodied in articles or reviews.

Copyright © 2022 by Spire Learning, LLC and its Licensors. All rights reserved. No part of this publication or activity may be reproduced or transmitted in any form, by any means, without prior written permission of Spire Learning, LLC. Spire Learning, LLC and Postgraduate Institute for Medicine will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication or activity, including any claims related to the products, drugs, or services mentioned herein.
 

COURSE VIEWING REQUIREMENTS

Supported Browsers:
Microsoft Edge
Google Chrome 60 or higher
Mozilla Firefox 60 or higher
Apple Safari 11.0 or higher
For video, install the latest version of Quicktime.		 Supported Phones & Tablets:
iOS 9.3 and higher
Android 7.0 (Nougat or higher)
Microsoft Windows 8
Chrome OS

 
Additional Recommendations and Requirements
Display Resolution & Color Depth Resolution
- 960 X 768 minimum
- 1024 X 768 recommended min.

Color Depth
- 8 bits (256 colors) minimum
- 16 bits (High colors) minimum
Audio - Microphone
- Speakers or headphones
- Audio recording support
Word Processing Software that can open, modify, and save documents in Rich Text Format (RTF). Microsoft Word and PowerPoint are recommended.

 

Schedule an event with a Standardized Patient
×